Clinical trial
A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
NCT06237920 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
- Lead sponsor
- The Netherlands Cancer Institute
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- February 19, 2024
- Completion date
- August 1, 2028
- Enrollment
- 90 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
antineoplastics toxicity, female urogenital diseases, female urogenital diseases and pregnancy complications, male urogenital diseases, neoplasms, neoplasms by site, urinary bladder diseases, urinary bladder neoplasm, urogenital diseases, urogenital neoplasms, urologic neoplasms